跳至主要内容
临床试验/ISRCTN46806801
ISRCTN46806801
已完成
未知

Discovery of novel biomarkers in peripheral arterial disease/metabolic syndrome

niversity of Dundee (UK)0 个研究点目标入组 80 人2007年6月19日

概览

阶段
未知
干预措施
未指定
疾病 / 适应症
Type 2 diabetes and peripheral arterial disease
发起方
niversity of Dundee (UK)
入组人数
80
状态
已完成
最后更新
8年前

概览

简要总结

暂无简介。

注册库
who.int
开始日期
2007年6月19日
结束日期
待定
最后更新
8年前
研究类型
Interventional
性别
All

研究者

发起方
niversity of Dundee (UK)

入排标准

入选标准

  • For Phase 1 study subjects with PAD and type 2 diabetes will be included. PAD will be defined as patients with classical symptoms of intermittent claudication plus an Ankle brachial Blood Pressure Index (ABPI) of \<0\.9, the accepted cut off level for such a diagnosis.
  • For Phase 2 study patients with short distance claudication (\<200 yards) will be selected for the walking study, as their walking distances are more reproducible (i.e. using the standardized Gardner walking treadmill protocol no more than 25% variation from 2 consecutive treadmill tests performed at least a week apart during the screening period). Patients for this second study will be type 2 diabetic patients not receiving insulin.

排除标准

  • 1\. Contraindication to thiazolidinedione group of drugs
  • 2\. Subjects taking sulphonylureas
  • 3\. Subjects with cardiovascular disease event within last three months (such as Myocardial Infarction \[MI], unstable angina and stroke)
  • 4\. For Phase 2 study, subjects having more than 25% variation from 2 consecutive treadmill tests performed at least a week apart

结局指标

主要结局

未指定

相似试验